| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 用于电子应用的氘代化合物 | CN200980162303.0 | 2009-12-21 | CN102596950A | 2012-07-18 | D·D·莱克洛克斯 |
| 本发明涉及可用于电子应用的氘代吲哚并咔唑化合物。本发明还涉及活性层包含此类氘代化合物的电子器件。 | ||||||
| 2 | Novel use of dopamine receptor agonist | JP8803388 | 1988-04-09 | JPS63258819A | 1988-10-26 | RUDORUFU MAAKUSUTAIN; HOSE PARASHIOSU |
| 3 | Indolophenantridines | JP1233385 | 1985-01-24 | JPS60197687A | 1985-10-07 | AREKUSANDAA HAAGENBATSUHA; MATSUKUSU PEETAA ZAIRAA; HANSU YUURUKU BUYUUTORITSUHI |
| 4 | Method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives | US10524441 | 2003-08-13 | US07632948B2 | 2009-12-15 | Alex H. Gouliaev; William Dalby Brown; Frank Wätjen |
| The present invention is directed to a method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives. | ||||||
| 5 | Process for the production of ergoline derivatives | US930692 | 1992-10-07 | US5371000A | 1994-12-06 | Heidi Hummel-Maquardt; Mario Kennecke; Alfred Weber; Klaus Nickisch; Gregor Haffer |
| A process for the production of ergoline derivatives of general formula I is described ##STR1## in which the bonds represent two single-bonds or a double bond and a single bond.R.sub.1 means a hydrogen atom or an alkyl group with 1-6 carbon atomsR.sub.2 symbolizes a hydrogen atom or an alkyl group with 1-6 carbon atoms,R.sub.3 represents a carboxyl group or a grouping of formula--CONR.sub.4 R.sub.5 or --NHCQNR.sub.6 R.sub.7with R.sub.4 and R.sub.5 meaning hydrogen or an alkyl radical with 1-6 carbons atoms optionally substituted by a hydroxy group and R.sub.6 and R.sub.7 meaning an alkyl group containing 1-4 carbon atoms and Q meaning an oxygen or sulfur atom. | ||||||
| 6 | Uses of dopamine receptor agonists | US178668 | 1988-04-07 | US4855306A | 1989-08-08 | Rudolf Markstein; Jose Palacios |
| Selective dopamine D1 receptor agonists for use in the treatment of primary degenerative dementia, depression, anxiety, obesity or schizophrenia. | ||||||
| 7 | Isoergoline compounds and uses thereof | US15586255 | 2017-05-03 | US09777016B2 | 2017-10-03 | Thomas Armer; Geoff McKinley; Scott Borland; Miguel Guzman |
| Provided herein are isoergoline compounds and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1A, 5-HT1B and 5-HT1D receptors without agonizing the 5-HT2B receptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B adrenergic alpha2A and/or the alpha2B receptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein. | ||||||
| 8 | Indolophenanthridines useful as dopaminergic and analgesic agents | US695191 | 1985-01-25 | US4634708A | 1987-01-06 | Alexander Hagenbach; Max P. Seiler; Hans J. Wuthrich |
| 4,6,6a,7,8,12b-hexahydro-indolo[4,3-ab]phenanthridines are useful as dopaminergic and analgesic agents. | ||||||
| 9 | Treatment of pediatric tumors | US12669134 | 2008-07-03 | US08829021B2 | 2014-09-09 | Claudio Pisano; Loredana Vesci; Paolo Carminati |
| A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of pediatric tumors such as for examplerhabdomyosarcoma, primitive neuroectodermal tumors (PNET) and neuroblastoma. | ||||||
| 10 | Tetrahydropyridoindole derivatives | US10598777 | 2005-03-07 | US07714132B2 | 2010-05-11 | Anja Fecher; Heinz Fretz; Kurt Hilpert; Markus Riederer |
| The invention relates to tetrahydropyridoindole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions comprising one or more of those compounds and methods of treatment comprising administration of said compounds. | ||||||
| 11 | 9-Azabicyclo(3.3.1) nonane intermediates for compounds useful in the treatment of CNS disorders | US530513 | 1983-09-09 | US4560757A | 1985-12-24 | Michael S. Hadley; Francis E. Blaney |
| Compounds of formula (I): ##STR1## wherein X is methoxy or ethoxy, Y is amino or C.sub.1-6 alkanoylamino, Z is hydrogen, chloro or bromo and R.sub.1 is methyl, chloro or fluoro, have anti-psychotic activity, and are useful in the treatment of CNS disorders. Intermediates for the above compounds are also disclosed. | ||||||
| 12 | DEUTERATED COMPOUNDS FOR ELECTRONIC APPLICATIONS | EP09851350.0 | 2009-12-21 | EP2493887A1 | 2012-09-05 | LECLOUX, Daniel, David |
| This invention relates to deuterated indolocarbazole compounds that are useful in electronic applications. It also relates to electronic devices in which the active layer includes such a deuterated compound. | ||||||
| 13 | DEUTERATED COMPOUNDS FOR ELECTRONIC APPLICATIONS | PCT/US2009/068976 | 2009-12-21 | WO2011059463A1 | 2011-05-19 | LECLOUX, Daniel, David |
This invention relates to deuterated indolocarbazole compounds that are useful in electronic applications. It also relates to electronic devices in which the active layer includes such a deuterated compound. |
||||||
| 14 | Indolophenanthridine, ihre Herstellung und Verwendung | EP85810015.9 | 1985-01-22 | EP0155903B1 | 1989-08-23 | Hagenbach, Alexander; Seiler, Max Peter; Wüthrich, Hans Jürg |
| 15 | Indolophenanthridine, ihre Herstellung und Verwendung | EP85810015.9 | 1985-01-22 | EP0155903A1 | 1985-09-25 | Hagenbach, Alexander; Seiler, Max Peter; Wüthrich, Hans Jürg |
Die Erfindung betrifft 4,6,6a,7,8,12b-Hexahydro- indolo[4,3-ab]- phenanthridine sowie Verfahren zu ihrer Herstellung und ihre Anwendung als Pharmazeutika. Die erfindungsgemässen Verbindungen weisen dopaminerge und analgetische Eigenschaften auf. |
||||||
| 16 | 전자 응용을 위한 중수소화된 화합물 | KR1020127013678 | 2009-12-21 | KR101761435B1 | 2017-07-25 | 레클로욱스,다니엘,데이비드 |
| 본발명은전자응용에유용한중수소화된인돌로카르바졸화합물에관한것이다. 본발명은또한활성층이그러한중수소화된화합물을포함하는전자소자에관한것이다. | ||||||
| 17 | 전자 응용을 위한 중수소화된 화합물 | KR1020127013678 | 2009-12-21 | KR1020120101032A | 2012-09-12 | 레클로욱스,다니엘,데이비드 |
| 본 발명은 전자 응용에 유용한 중수소화된 인돌로카르바졸 화합물에 관한 것이다. 본 발명은 또한 활성 층이 그러한 중수소화된 화합물을 포함하는 전자 소자에 관한 것이다. | ||||||
| 18 | 신규한 이소퀴놀린 화합물 및 이를 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 조성물 | KR1020160130726 | 2016-10-10 | KR101844358B1 | 2018-04-02 | 허강민; 이일영; 강기동; 원민호; 육재민; 염현석 |
| 본발명은신규한이소퀴놀린화합물을유효성분으로포함하는염증성질환의예방또는치료용조성물에관한것이다. 본발명에따른신규한이소퀴놀린화합물은 NF-kB(Nnclear factor kappa B) 활성을저해하고, TLR4 신호전달경로의유전자발현을감소시키며, 염증성사이토카인의발현을억제함으로써염증을효과적으로완화시키는효과를가지고있어, 염증성질환의예방또는치료에유용하게사용될수 있다. | ||||||
| 19 | Long Stokes shift chromenoquinoline dyes and uses in sequencing applications | AU2021401162 | 2021-12-16 | AU2021401162A1 | 2023-01-05 | CRESSINA ELENA; FRANCAIS ANTOINE; LIU XIAOHAI |
| The present application relates to long Stokes shift chromenoquinoline dyes and their uses as fluorescent labels. For example, these dyes may be used to label nucleotides for nucleic acid sequencing applications. The chromenoquinoline dyes have Formula (I). | ||||||
| 20 | СКОНДЕНСИРОВАННЫЕ ГЕКСАЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | EA199600018 | 1996-04-09 | EA199600018A3 | 1997-03-31 | KAMIHARA SHINJI; KANAI KAZAKI; NOGUCHI SHIGERU; TERASAWA HIROFUMI; KITAOKA HIROAKI |
| Изобретениеотноситсяк производномукапотецинаформулы I, обладающемупротивоопухолевойактивностью, ик способуполученияэтогосоединения, которыйвключаетобработкусоединенияформулы II метансульфоновойкислотойи последующуюперекристаллизациюполученногопродукта:Изобретениеотноситсятакжек фармацевтическойкомпозиции, содержащейсоединениеформулы I илиегогидрати фармацевтическиприемлемуюсоль. | ||||||
QQ群二维码
意见反馈
意见反馈